Thyroid Research最新文献

{"title":"Undetectable thyroglobulin makes ¹²³I whole-body scan and stimulated thyroglobulin obsolete in follow-up care of differentiated thyroid cancer: a retrospective study.","authors":"Bastiaan Sol,&nbsp;Bert Bravenboer,&nbsp;Brigitte Velkeniers,&nbsp;Steven Raeymaeckers,&nbsp;Marleen Keyaerts,&nbsp;Corina Emilia Andreescu","doi":"10.1186/s13044-021-00114-0","DOIUrl":"https://doi.org/10.1186/s13044-021-00114-0","url":null,"abstract":"<p><strong>Background: </strong>Differentiated thyroid cancer (DTC) is a common malignancy with increasing incidence. Follow-up care for DTC includes thyroglobulin (Tg) measurement and ultrasound (US) of the neck, combined with ¹³¹I remnant ablation when indicated. Diagnostic precision has evolved with the introduction of the new high-sensitive Tg-assays (sensitivity ≤0.1 ng/mL). The aim of the study was to determine the prognostic utility of high-sensitive Tg and the need for other diagnostic tests in DTC.</p><p><strong>Methods: </strong>This was a retrospective, observational study. Patients with pathologically confirmed DTC, treated with total thyroidectomy and ¹³¹I remnant ablation, who had their complete follow-up care in our institution were selected (October 2013-December 2018). Subjects with possible thyroglobulin autoantibody interference were excluded. Statistical analysis was performed using the IBM SPSS® Statistics 24 software package.</p><p><strong>Results: </strong>Forty patients were eligible for analysis. A total of 24 out of the 40 patients (60%) had an undetectable high-sensitive Tg 6 months after total thyroidectomy. None of these patients had a stimulated Tg above 1 ng/mL, or remnant on the ¹²³I Whole-Body Scan (WBS) after 1 year of follow-up. Ultrasound of the neck, performed between 6 and 12 months postoperative, was negative in 21 out of the 24 patients.</p><p><strong>Conclusions: </strong>This study shows that an undetectable high-sensitive Tg can change the management of patients with DTC and decrease the use and need of stimulated Tg and ¹²³I WBS.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"14 1","pages":"23"},"PeriodicalIF":2.2,"publicationDate":"2021-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39533222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between thyroid function and ovarian reserve: a prospective cross-sectional study.","authors":"Roya Kabodmehri,&nbsp;Seyedeh Hajar Sharami,&nbsp;Ziba Zahiri Sorouri,&nbsp;Nasrin Ghanami Gashti,&nbsp;Forozan Milani,&nbsp;Zeinab Chaypaz,&nbsp;Maryam Ghalandari","doi":"10.1186/s13044-021-00112-2","DOIUrl":"https://doi.org/10.1186/s13044-021-00112-2","url":null,"abstract":"<p><strong>Background: </strong>Thyroid dysfunction can affect fertility and miscarriage risk by affecting the process of follicular growth, embryo development, implantation, and placental formation. It has been suggested that thyroid disorders are associated with ovarian reserve by affecting the follicular process. The aim of the present study was to investigate the relationship between thyroid hormone levels and ovarian reserve.</p><p><strong>Methods: </strong>Three hundred fourteen women with infertility due to various etiologies were enrolled in this study (172 individuals with Anti-Mullerian hormone (AMH) level ≥ 1.1 ng/ml and 142 individuals with AMH < 1.1 ng/ml). Serum levels of follicle-stimulating hormone (FSH), estradiol (E2) on day 2-4 of menstrual cycles, AMH, Thyroid-stimulating hormone (TSH), and thyroxine (free T4) were evaluated.</p><p><strong>Results: </strong>In participants with age over 35 years, median TSH level in women with AMH < 1.1 ng/ml was significantly higher than those with AMH ≥1.1 ng/ml (P-value =0.037). There was no significant difference in body mass index (BMI) in patients with age older than 35 years and younger than 35 years sub-groups based on AMH level (P-value = 0.102, and P-value = 0.909 respectively). With one unit increase in TSH level, the odds of having AMH < 1.1 ng/ml increases by 1.25 times or by 25% (P-value =0.017). Receiver operator characteristic (ROC) curve analysis showed a TSH cut-off point of 1.465 mIU/L in participants over 35 years in identifying decreased AMH level.</p><p><strong>Conclusion: </strong>Our study supports the relationship between TSH level and ovarian reserve so that with an increase in TSH from a certain level is associated with a decrease in ovarian function.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"14 1","pages":"22"},"PeriodicalIF":2.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39477684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between thyroid disorders and COVID-19: a protocol for a systematic review and meta-analysis.","authors":"Soraya Doustmohammadian,&nbsp;Azam Doustmohammadian,&nbsp;Marjan Momeni","doi":"10.1186/s13044-021-00113-1","DOIUrl":"https://doi.org/10.1186/s13044-021-00113-1","url":null,"abstract":"<p><strong>Background: </strong>The novel coronavirus (COVID-19) epidemic initially appeared in Wuhan, Hubei Province, China, on 31 December 2019 and was spread rapidly worldwide. Most underlying diseases reported with COVID-19 patients are diabetes, hypertension, coronary heart diseases, and cerebrovascular disease. We do not know whether individuals with thyroid disease are at increased risk of COVID-19 infection.</p><p><strong>Methods: </strong>Two experienced researchers will conduct an electronic search of the databases including PubMed/MEDLINE, the Cochrane Reviews, and the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Scopus, and ProQuest, for articles published since October 2019. Clinical trials and observational studies will be included. Studies will be screened after de-duplication. A standardized data extraction form will be developed through discussions with the review team and will be revised after piloting. An appropriate risk of bias assessment tool will be used to assess the quality of studies. Two independent reviewers will assess the eligibility, extraction of detailed information, and quality assessment of studies. The results will be pooled for meta-analysis, subgroup analysis and/or descriptive analysis based on the included data conditions.</p><p><strong>Conclusion: </strong>Results of this study will provide current evidence on the association of COVID-19 diseases with any thyroid disorders such as hypothyroidism, thyrotoxicosis, and thyroid cancer with or without radioiodine therapy. Findings will be disseminated in peer-reviewed publications and conference presentations.</p><p><strong>Trial registration: </strong>PROSPERO registration number: CRD42020184289. https://www.crd.york.ac.uk/PROSPERO/#recordDetails.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"14 1","pages":"21"},"PeriodicalIF":2.2,"publicationDate":"2021-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39469119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence of carcinoma showing thymus-like differentiation (CASTLE) involving the thyroid gland.","authors":"N V Dang,&nbsp;L X Son,&nbsp;N T T Hong,&nbsp;N T T Nhung,&nbsp;N T Tung,&nbsp;L V Quang","doi":"10.1186/s13044-021-00111-3","DOIUrl":"https://doi.org/10.1186/s13044-021-00111-3","url":null,"abstract":"<p><strong>Background: </strong>Carcinoma showing thymus-like differentiation (CASTLE) in the thyroid gland is a rare disease with generally a favorable prognosis. Treatment with surgery and adjuvant radiotherapy has been shown to improve local control and long-term survival rates. In this report, we present a case of a recurrent thyroid gland CASTLE and review the literature on the diagnosis and treatment of this disease.</p><p><strong>Case presentation: </strong>A 60-year-old woman, who was diagnosed with a CASTLE thyroid tumor in 2015, had a total thyroidectomy and was maintained on thyroid hormone replacement (levothyroxine). After 5 years, the patient had a recurrence, in an advanced stage unsuitable for surgery. As the patient declined to undergo radiotherapy, she was followed up without intervention and is currently stable after 15 months.</p><p><strong>Conclusions: </strong>CASTLE is a rare disease, diagnosed based on postoperative pathology and immunohistochemistry analysis, especially upon CD5 marker. In case of relapse, treatment options include surgery and radiotherapy; however conservative management without intervention is an acceptable alternative in some cases.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"14 1","pages":"20"},"PeriodicalIF":2.2,"publicationDate":"2021-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39329158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of metastatic poorly differentiated thyroid cancer from a sub-centimeter papillary thyroid carcinoma in a young patient with a germline MET mutation - association or random chance?","authors":"Klara Johansson,&nbsp;Adam Stenman,&nbsp;Johan O Paulsson,&nbsp;Na Wang,&nbsp;Catharina Ihre-Lundgren,&nbsp;Jan Zedenius,&nbsp;C Christofer Juhlin","doi":"10.1186/s13044-021-00110-4","DOIUrl":"https://doi.org/10.1186/s13044-021-00110-4","url":null,"abstract":"<p><strong>Background: </strong>Thyroid cancer dedifferentiation is an unusual observation among young patients and is poorly understood, although a recent correlation to DICER1 gene mutations has been proposed.</p><p><strong>Case presentation: </strong>A 28-year old patient presented with a sub-centimeter cytology-verified primary papillary thyroid carcinoma (PTC) and a synchronous lateral lymph node metastasis. Following surgery, histopathology confirmed a 9 mm oxyphilic PTC and a synchronous metastasis of poorly differentiated thyroid carcinoma (PDTC). Extensive molecular examinations of both lesions revealed wildtype DICER1 sequences, but identified a somatic ETV6-NTRK3 gene fusion and a MET germline variant (c.1076G > A, p.Arg359Gln). MET is an established oncogene known to be overexpressed in thyroid cancer, and this specific alteration was not reported as a single nucleotide polymorphism (SNP), suggestive of a mutation. Both the primary PTC and the metastatic PDTC displayed strong MET immunoreactivity. A validation cohort of 50 PTCs from young patients were analyzed using quantitative real-time PCR, revealing significantly higher MET gene expression in tumors than normal thyroid controls, a finding which was particularly pronounced in BRAF V600E mutated cases. No additional tumors apart from the index case harbored the p.Arg359Gln MET mutation. Transfecting PTC cell lines MDA-T32 and MDA-T41 with a p.Arg359Gln MET plasmid construct revealed no obvious effects on cellular migratory or invasive properties, whereas overexpression of wildtype MET stimulated invasion.</p><p><strong>Conclusions: </strong>The question of whether the observed MET mutation in any way influenced the dedifferentiation of a primary PTC into a PDTC metastasis remains to be established. Moreover, our data corroborate earlier studies, indicating that MET is aberrantly expressed in PTC and may influence the invasive behavior of these tumors.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"14 1","pages":"19"},"PeriodicalIF":2.2,"publicationDate":"2021-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39308180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to use thionamide anti-thyroid drug in the young- what's new?","authors":"Tim Cheetham","doi":"10.1186/s13044-021-00109-x","DOIUrl":"https://doi.org/10.1186/s13044-021-00109-x","url":null,"abstract":"<p><p>The excess thyroid hormone secretion that characterises Graves' disease (GD) is generated when stimulatory antibodies bind to the thyroid stimulating hormone receptor on the follicular cell of the thyroid gland.This underlying mechanism cannot easily be abolished and the mainstay of Graves' disease (GD) management in the young remains thionamide anti-thyroid drug (ATD). Unfortunately, GD will usually recur after a 2 or 3 year course of ATD, even when the stimulatory antibody titres have fallen. The diagnosis of GD therefore usually signals the start of a lengthy period of out-patient assessments and associated venepuncture. Careful, more protracted administration of ATD may increase the likelihood of longer-term remission and reduce the likelihood of the patient developing ATD side-effects. An understanding of how best to use ATD and an awareness of the less well-known consequences of GD and its' treatment - such as excessive weight-gain and long-term hypothyroidism - are also of fundamental importance.Recent clinical studies have shed light on how best to manage the young patient with GD and the associated new information will help to answer some of the questions posed by the young person and their family at diagnosis. This new knowledge is the focus of this article about ATD therapy in the young.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"14 1","pages":"18"},"PeriodicalIF":2.2,"publicationDate":"2021-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13044-021-00109-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39206969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Falsely diagnosed thyrotoxicosis caused by anti-streptavidin antibodies and pre-wash procedures.","authors":"Takuya Ishikawa,&nbsp;Hiroyuki Sakai,&nbsp;Tokutaro Itaya,&nbsp;Suwanai Hirotsugu,&nbsp;Jumpei Shikuma,&nbsp;Takashi Miwa,&nbsp;Ryo Suzuki,&nbsp;Masato Odawara","doi":"10.1186/s13044-021-00108-y","DOIUrl":"https://doi.org/10.1186/s13044-021-00108-y","url":null,"abstract":"<p><strong>Background: </strong>Anti-streptavidin antibodies are causal determinants of analytical interference during Thyroid function tests, and numerous reports have detailed such interference, with anti-streptavidin antibodies attracting attention.</p><p><strong>Case presentation: </strong>We conducted a straightforward investigation of interference due to anti-streptavidin antibodies, with a case of a 60-year-old Japanese man who consulted our department for inconsistencies between his clinical course and Thyroid function tests. Experiments were conducted using Cobas8000 e602, which employs assay procedures with pre-wash to evaluate FT4 and FT3 levels.</p><p><strong>Conclusions: </strong>To our knowledge, this is the first published report to clearly investigate such interferences using a combination of polyethylene glycol precipitation, heterophilic blocking tube precipitation, streptavidin-coated magnetic particle precipitation, and different instruments with or without pre-wash. Clinicians should consider that interferences caused by anti-streptavidin antibodies could lead to a misdiagnosis of thyrotoxicosis. Moreover, discussions between laboratory specialists, clinicians, and manufacturers are required to identify interferences and avoid unnecessary examinations and inappropriate treatment.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"14 1","pages":"17"},"PeriodicalIF":2.2,"publicationDate":"2021-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13044-021-00108-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39171685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced thyroid carcinomas: neural network analysis of ultrasonographic characteristics.","authors":"Michael Cordes,&nbsp;Theresa Ida Götz,&nbsp;Elmar Wolfgang Lang,&nbsp;Stephan Coerper,&nbsp;Torsten Kuwert,&nbsp;Christian Schmidkonz","doi":"10.1186/s13044-021-00107-z","DOIUrl":"https://doi.org/10.1186/s13044-021-00107-z","url":null,"abstract":"<p><strong>Background: </strong>Ultrasound is the first-line imaging modality for detection and classification of thyroid nodules. Certain characteristics observable by ultrasound have recently been identified that may indicate malignancy. This retrospective cohort study was conducted to test the hypothesis that advanced thyroid carcinomas show distinctive clinical and sonographic characteristics. Using a neural network model as proof of concept, nine clinical/sonographic features served as input.</p><p><strong>Methods: </strong>All 96 study enrollees had histologically confirmed thyroid carcinomas, categorized (n = 32, each) as follows: group 1, advanced carcinoma (ADV) marked by local invasion or distant metastasis; group 2, non-advanced papillary carcinoma (PTC); or group 3, non-advanced follicular carcinoma (FTC). Preoperative ultrasound profiles were obtained via standardized protocols. The neural network had nine input neurons and one hidden layer.</p><p><strong>Results: </strong>Mean age and the number of male patients in group 1 were significantly higher compared with groups 2 (p = 0.005) or 3 (p <  0.001). On ultrasound, tumors of larger volume and irregular shape were observed significantly more often in group 1 compared with groups 2 (p <  0.001) or 3 (p ≤ 0.01). Network accuracy in discriminating advanced vs. non-advanced tumors was 84.4% (95% confidence interval [CI]: 75.5-91), with positive and negative predictive values of 87.1% (95% CI: 70.2-96.4) and 92.3% (95% CI: 83.0-97.5), respectively.</p><p><strong>Conclusions: </strong>Our study has shown some evidence that advanced thyroid tumors demonstrate distinctive clinical and sonographic characteristics. Further prospective investigations with larger numbers of patients and multicenter design should be carried out to show whether a neural network incorporating these features may be an asset, helping to classify malignancies of the thyroid gland.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"14 1","pages":"16"},"PeriodicalIF":2.2,"publicationDate":"2021-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13044-021-00107-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39121157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papillary thyroid microcarcinoma with lung metastases: a case report and review of the literature.","authors":"Tadafumi Shimizu,&nbsp;Takaaki Oba,&nbsp;Tatsunori Chino,&nbsp;Ai Soma,&nbsp;Mayu Ono,&nbsp;Tokiko Ito,&nbsp;Toshiharu Kanai,&nbsp;Kazuma Maeno,&nbsp;Yoshinori Sato,&nbsp;Takeshi Uehara,&nbsp;Ken-Ichi Ito","doi":"10.1186/s13044-021-00106-0","DOIUrl":"https://doi.org/10.1186/s13044-021-00106-0","url":null,"abstract":"<p><strong>Background: </strong>Distant metastasis from papillary thyroid microcarcinoma (PTMC) is rare. Here we report a case of PTMC with multiple lung metastases.</p><p><strong>Case presentation: </strong>A 64-year-old man presented to our hospital with abdominal pain. Computed tomography incidentally revealed multiple lung nodules. The lung tumor was histologically diagnosed as metastasis of papillary thyroid carcinoma (PTC) by core needle biopsy via thoracoscopy. The patient was referred to our department for further examination. Neck ultrasonography revealed a 0.9 cm hypoechoic nodule in the right lobe of the thyroid gland, which was diagnosed as PTC by fine-needle aspiration cytology. Subsequently, total thyroidectomy was performed, followed by radioiodine therapy. Iodine-131 (131-I) scintigraphy showed a strong accumulation in the lung metastasis. The patient presented no evidence of progression of lung metastasis for 25 months after the operation.</p><p><strong>Conclusions: </strong>Lymph node metastasis or extraglandular extension has been reported in the few published cases of metastatic PTMC, including the present case, and the average age of these cases was 58.8 ± 12.0 years. Although active surveillance without surgical resection is expected to become a standard of care for PTMC, this case indicates that a subset of PTMC patients with risk factors may develop distant metastases. Hence, careful preoperative screening is required to avoid complications associated with completion thyroidectomy.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"14 1","pages":"15"},"PeriodicalIF":2.2,"publicationDate":"2021-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13044-021-00106-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39083872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between maternal urinary iodine assessment, dietary iodine intakes and neurodevelopmental outcomes in the child: a systematic review.","authors":"Anna M Monaghan,&nbsp;Maria S Mulhern,&nbsp;Emeir M McSorley,&nbsp;J J Strain,&nbsp;Matthew Dyer,&nbsp;Edwin van Wijngaarden,&nbsp;Alison J Yeates","doi":"10.1186/s13044-021-00105-1","DOIUrl":"10.1186/s13044-021-00105-1","url":null,"abstract":"<p><strong>Objective: </strong>Mild to moderate iodine deficiency during pregnancy has been associated with adverse neurodevelopmental outcomes in offspring. Few research studies to date combine assessment of urinary iodine (UIC and/or ICr), biomarkers that best reflect dietary intake, with reported dietary intake of iodine rich foods in their assessment of iodine deficiency. Thus, a systematic review was conducted to incorporate both these important measures.</p><p><strong>Design: </strong>Using PRISMA guidelines, a comprehensive search was conducted in three electronic databases (EMBASE®, MedLine® and Web of Science®) from January 1970-March 2021. Quality assessment was undertaken using the Newcastle Ottawa Scale. Eligible studies included reported assessment of iodine status through urinary iodine (UIC and/or ICr) and/or dietary intake measures in pregnancy alongside neurodevelopmental outcomes measured in the children. Data extracted included study author, design, sample size, country, gestational age, child age at testing, cognitive tests, urinary iodine assessment (UIC in μg/L and/or ICr in μg/g), dietary iodine intake assessment and results of associations for the assessed cognitive outcomes.</p><p><strong>Results: </strong>Twelve studies were included with nine reporting women as mild-moderately iodine deficient based on World Health Organization (WHO) cut-offs for urinary iodine measurements < 150 μg/l, as the median UIC value in pregnant women. Only four of the nine studies reported a negative association with child cognitive outcomes based on deficient urinary iodine measurements. Five studies reported urinary iodine measurements and dietary intakes with four of these studies reporting a negative association of lower urinary iodine measurements and dietary iodine intakes with adverse offspring neurodevelopment. Milk was identified as the main dietary source of iodine in these studies.</p><p><strong>Conclusion: </strong>The majority of studies classified pregnant women to be mild-moderately iodine deficient based on urinary iodine assessment (UIC and/or ICr) and/or dietary intakes, with subsequent offspring neurodevelopment implications identified. Although a considerable number of studies did not report an adverse association with neurodevelopmental outcomes, these findings are still supportive of ensuring adequate dietary iodine intakes and urinary iodine monitoring throughout pregnancy due to the important role iodine plays within foetal neurodevelopment. This review suggests that dietary intake data may indicate a stronger association with cognitive outcomes than urinary iodine measurements alone. The strength of this review distinguishes results based on cognitive outcome per urinary iodine assessment strategy (UIC and/or ICr) with dietary data. Future work is needed respecting the usefulness of urinary iodine assessment (UIC and/or ICr) as an indicator of deficiency whilst also taking account of dietary intakes.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"14 1","pages":"14"},"PeriodicalIF":2.2,"publicationDate":"2021-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13044-021-00105-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39071785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}